Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data

Tiphanie P. Vogel; Karina A. Top; Christos Karatzios; David C. Hilmers; Lorena I. Tapia; Pamela Moceri; Lisa Giovannini-Chami; Nicholas Wood; Rebecca E. Chandler; Nicola P. Klein; Elizabeth P. Schlaudecker; M. Cecilia Poli; Eyal Muscal; Flor M. Munoz

doi:10.1016/j.vaccine.2021.01.054

Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data

Tiphanie P. Vogel, Karina A. Top, Christos Karatzios, David C. Hilmers, Lorena I. Tapia, Pamela Moceri, Lisa Giovannini-Chami, Nicholas Wood, Rebecca E. Chandler, Nicola P. Klein, Elizabeth P. Schlaudecker, M. Cecilia Poli, Eyal Muscal, Flor M. Munoz

Medicine

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

183 Citas (Scopus)

Resumen

This is a Brighton Collaboration Case Definition of the term “Multisystem Inflammatory Syndrome in Children and Adults (MIS-C/A)” to be utilized in the evaluation of adverse events following immunization. The case definition was developed by topic experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2. The format of the Brighton Collaboration was followed, including an exhaustive review of the literature, to develop a consensus definition and defined levels of certainty. The document underwent peer review by the Brighton Collaboration Network and by selected expert external reviewers prior to submission. The comments of the reviewers were taken into consideration and edits incorporated into this final manuscript.

Idioma original	English
Páginas (desde-hasta)	3037-3049
Número de páginas	13
Publicación	Vaccine
Volumen	39
N.º	22
DOI	https://doi.org/10.1016/j.vaccine.2021.01.054
Estado	Published - may. 21 2021

Nota bibliográfica

Funding Information:
The authors are grateful for the support and helpful comments provided by the Brighton Collaboration and SPEAC Steering Committee (Barbara Law) and reference peer review group, as well as other experts consulted as part of the process, including Drs. Marco Cattalini and Andrea Taddio for sharing unpublished cohort information. The authors are also grateful to Matt Dudley of the Brighton Collaboration Secretariat for revisions of the final document. We acknowledge the financial support provided by the Coalition for Epidemic Preparedness Innovations (CEPI) for our work under a service order entitled Safety Platform for Emergency vACcines (SPEAC) Project with the Brighton Collaboration, a program of the Task Force for Global Health, Decatur, GA.

Funding Information:
The authors are grateful for the support and helpful comments provided by the Brighton Collaboration and SPEAC Steering Committee (Barbara Law) and reference peer review group, as well as other experts consulted as part of the process, including Drs. Marco Cattalini and Andrea Taddio for sharing unpublished cohort information. The authors are also grateful to Matt Dudley of the Brighton Collaboration Secretariat for revisions of the final document. We acknowledge the financial support provided by the Coalition for Epidemic Preparedness Innovations (CEPI) for our work under a service order entitled Safety Platform for Emergency vACcines (SPEAC) Project with the Brighton Collaboration, a program of the Task Force for Global Health, Decatur, GA.

Publisher Copyright:
© 2021 The Author(s)

ASJC Scopus Subject Areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't
Review

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1016/j.vaccine.2021.01.054

Otros archivos y enlaces

Citar esto

Vogel, T. P., Top, K. A., Karatzios, C., Hilmers, D. C., Tapia, L. I., Moceri, P., Giovannini-Chami, L., Wood, N., Chandler, R. E., Klein, N. P., Schlaudecker, E. P., Poli, M. C., Muscal, E., & Munoz, F. M. (2021). Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 39(22), 3037-3049. https://doi.org/10.1016/j.vaccine.2021.01.054

Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. / Vogel, Tiphanie P.; Top, Karina A.; Karatzios, Christos et al.
En: Vaccine, Vol. 39, N.º 22, 21.05.2021, p. 3037-3049.

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

Vogel, TP, Top, KA, Karatzios, C, Hilmers, DC, Tapia, LI, Moceri, P, Giovannini-Chami, L, Wood, N, Chandler, RE, Klein, NP, Schlaudecker, EP, Poli, MC, Muscal, E & Munoz, FM 2021, 'Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data', Vaccine, vol. 39, n.º 22, pp. 3037-3049. https://doi.org/10.1016/j.vaccine.2021.01.054

@article{799b7bf448e942ad9b69b6621c81a279,

title = "Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data",

abstract = "This is a Brighton Collaboration Case Definition of the term “Multisystem Inflammatory Syndrome in Children and Adults (MIS-C/A)” to be utilized in the evaluation of adverse events following immunization. The case definition was developed by topic experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2. The format of the Brighton Collaboration was followed, including an exhaustive review of the literature, to develop a consensus definition and defined levels of certainty. The document underwent peer review by the Brighton Collaboration Network and by selected expert external reviewers prior to submission. The comments of the reviewers were taken into consideration and edits incorporated into this final manuscript.",

author = "Vogel, {Tiphanie P.} and Top, {Karina A.} and Christos Karatzios and Hilmers, {David C.} and Tapia, {Lorena I.} and Pamela Moceri and Lisa Giovannini-Chami and Nicholas Wood and Chandler, {Rebecca E.} and Klein, {Nicola P.} and Schlaudecker, {Elizabeth P.} and Poli, {M. Cecilia} and Eyal Muscal and Munoz, {Flor M.}",

note = "Funding Information: The authors are grateful for the support and helpful comments provided by the Brighton Collaboration and SPEAC Steering Committee (Barbara Law) and reference peer review group, as well as other experts consulted as part of the process, including Drs. Marco Cattalini and Andrea Taddio for sharing unpublished cohort information. The authors are also grateful to Matt Dudley of the Brighton Collaboration Secretariat for revisions of the final document. We acknowledge the financial support provided by the Coalition for Epidemic Preparedness Innovations (CEPI) for our work under a service order entitled Safety Platform for Emergency vACcines (SPEAC) Project with the Brighton Collaboration, a program of the Task Force for Global Health, Decatur, GA. Funding Information: The authors are grateful for the support and helpful comments provided by the Brighton Collaboration and SPEAC Steering Committee (Barbara Law) and reference peer review group, as well as other experts consulted as part of the process, including Drs. Marco Cattalini and Andrea Taddio for sharing unpublished cohort information. The authors are also grateful to Matt Dudley of the Brighton Collaboration Secretariat for revisions of the final document. We acknowledge the financial support provided by the Coalition for Epidemic Preparedness Innovations (CEPI) for our work under a service order entitled Safety Platform for Emergency vACcines (SPEAC) Project with the Brighton Collaboration, a program of the Task Force for Global Health, Decatur, GA. Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2021",

month = may,

day = "21",

doi = "10.1016/j.vaccine.2021.01.054",

language = "English",

volume = "39",

pages = "3037--3049",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "22",

}

TY - JOUR

T1 - Multisystem inflammatory syndrome in children and adults (MIS-C/A)

T2 - Case definition & guidelines for data collection, analysis, and presentation of immunization safety data

AU - Vogel, Tiphanie P.

AU - Top, Karina A.

AU - Karatzios, Christos

AU - Hilmers, David C.

AU - Tapia, Lorena I.

AU - Moceri, Pamela

AU - Giovannini-Chami, Lisa

AU - Wood, Nicholas

AU - Chandler, Rebecca E.

AU - Klein, Nicola P.

AU - Schlaudecker, Elizabeth P.

AU - Poli, M. Cecilia

AU - Muscal, Eyal

AU - Munoz, Flor M.

N1 - Funding Information: The authors are grateful for the support and helpful comments provided by the Brighton Collaboration and SPEAC Steering Committee (Barbara Law) and reference peer review group, as well as other experts consulted as part of the process, including Drs. Marco Cattalini and Andrea Taddio for sharing unpublished cohort information. The authors are also grateful to Matt Dudley of the Brighton Collaboration Secretariat for revisions of the final document. We acknowledge the financial support provided by the Coalition for Epidemic Preparedness Innovations (CEPI) for our work under a service order entitled Safety Platform for Emergency vACcines (SPEAC) Project with the Brighton Collaboration, a program of the Task Force for Global Health, Decatur, GA. Funding Information: The authors are grateful for the support and helpful comments provided by the Brighton Collaboration and SPEAC Steering Committee (Barbara Law) and reference peer review group, as well as other experts consulted as part of the process, including Drs. Marco Cattalini and Andrea Taddio for sharing unpublished cohort information. The authors are also grateful to Matt Dudley of the Brighton Collaboration Secretariat for revisions of the final document. We acknowledge the financial support provided by the Coalition for Epidemic Preparedness Innovations (CEPI) for our work under a service order entitled Safety Platform for Emergency vACcines (SPEAC) Project with the Brighton Collaboration, a program of the Task Force for Global Health, Decatur, GA. Publisher Copyright: © 2021 The Author(s)

PY - 2021/5/21

Y1 - 2021/5/21

N2 - This is a Brighton Collaboration Case Definition of the term “Multisystem Inflammatory Syndrome in Children and Adults (MIS-C/A)” to be utilized in the evaluation of adverse events following immunization. The case definition was developed by topic experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2. The format of the Brighton Collaboration was followed, including an exhaustive review of the literature, to develop a consensus definition and defined levels of certainty. The document underwent peer review by the Brighton Collaboration Network and by selected expert external reviewers prior to submission. The comments of the reviewers were taken into consideration and edits incorporated into this final manuscript.

AB - This is a Brighton Collaboration Case Definition of the term “Multisystem Inflammatory Syndrome in Children and Adults (MIS-C/A)” to be utilized in the evaluation of adverse events following immunization. The case definition was developed by topic experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2. The format of the Brighton Collaboration was followed, including an exhaustive review of the literature, to develop a consensus definition and defined levels of certainty. The document underwent peer review by the Brighton Collaboration Network and by selected expert external reviewers prior to submission. The comments of the reviewers were taken into consideration and edits incorporated into this final manuscript.

UR - http://www.scopus.com/inward/record.url?scp=85101541214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101541214&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2021.01.054

DO - 10.1016/j.vaccine.2021.01.054

M3 - Review article

C2 - 33640145

AN - SCOPUS:85101541214

SN - 0264-410X

VL - 39

SP - 3037

EP - 3049

JO - Vaccine

JF - Vaccine

IS - 22

ER -

Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto